Comparative Effectiveness of Di'ao Xin Xue Kang Capsule and Compound Danshen Tablet in Patients With Symptomatic Chronic Stable Angina

Abstract

A high proportion of patients with stable angina remains symptomatic despite multiple treatment options. Di'ao Xinxuekang (XXK) capsule and Compound Danshen (CDS) tablet have been approved for treating angina pectoris for more than 20 years in China. We compare the anti-anginal effectiveness of XXK capsule and CDS tablet in patients with symptomatic chronic stable angina. A randomized, multicenter, double-blind, parallel-group, superiority trial was conducted in 4 study sites. 733 patients with symptomatic chronic stable angina were included in the full analysis set. The primary outcomes were the proportion of patients who were angina-free and the proportion of patients with normal electrocardiogram (ECG) recordings during 20 weeks treatment. Compared with CDS, XXK significantly increased the proportion of angina-free patients, but no significant difference was noted in the proportion of patients with normal ECG recordings. Weekly angina frequency and nitroglycerin use were significantly reduced with XXK versus CDS at week 20. Moreover, XXK also improved the quality of life of angina patients as measured by the SAQ score and Xueyu Zheng (a type of TCM syndrome) score. We demonstrate that XXK capsule is more effective for attenuating anginal symptoms and improving quality of life in patients with symptomatic chronic stable angina, compared with CDS tablet.

Potent effects of dioscin against pancreatic cancer via miR‐149‐3P‐mediated inhibition of the Akt1 signalling pathway

“…Dioscin is one major active ingredient of some medicinal herbs including Discorea nipponica Makino and Rhizoma dioscoreae , and some TCMs including Liuwei Dihuang decoction (LW), Di'ao Xinxuekang (Di'ao XXK) and Shuyu Zaogan tablets, which have been widely used to treat various diseases including dementia, osteoporosis and diabetics (Zhang et al, ; Yu et al, ; Zhou et al, ). Furthermore, Di'ao XXK has been allowed to register in the European Union market in 2012.…”

Danhong injection in the treatment of chronic stable angina: study protocol for a randomized controlled trial

“…For serious adverse events, the investigator must immediately take necessary measures, report to the principal investigator and the ethics committee, and place a record on the case report form including a signature and the date. The classification of the severity of adverse events and their relationship to the studied drug will be conducted according to the methods in our previous study [ 33 ].…”

Evaluating the effects of Danhong injection in treatment of acute ischemic stroke: study protocol for a multicenter randomized controlled trial

“…If a SAE occurs, the investigator must immediately report it to the principal investigator and the ethics committee, and record it on the CRF with a signature and date. The classification of the severity of AEs and relationship to the studied drug are conducted according to our previous study [ 18 ].…”